title: The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
abstract: OBJECTIVE
  The value of the serum tumor marker CA125 in borderline tumors of the ovary (BOTs) is not well defined, with unclear benefit in both diagnosis and follow-up. The aim of the present project was to identify the predictive value of CA125 for stage and relapse.
  
  
  METHODS
  CA125 data were extracted from the ROBOT multicenter study of patients with BOT treated between 1998 and 2008 in 24 German centers. While patients' data were retrieved retrospectively from hospital records and clinical tumor registries, follow-up and independent central pathology review were performed prospectively.
  
  
  RESULTS
  We identified 127 patients from the ROBOT database fulfilling the eligibility criterion of available CA125 at initial diagnosis. Eighty-three (65.3%) patients had increased CA125 levels (>35 U/L). Of the patients, 85.0% presented with serous and 13.4% with mucinous BOT histology, whereas 29.9% had stage I disease. Fifteen (11.8%) patients experienced a relapse. Multivariate analysis identified raised CA125, young age, and serous histology as independent predictors of peritoneal implants of any type at initial presentation. Raised CA125 at initial diagnosis was, however, not an independent predictor of future relapse.
  
  
  CONCLUSIONS
  Elevated CA125 seems to be associated with the presence of peritoneal implants of any type at initial diagnosis of serous BOT, but failed to have any independent predictive value on future relapse. Prospective multicenter studies are warranted to evaluate CA125 measurements in the follow-up management of BOT.
authors.affiliation: *Department of Gynecology Charité, Campus Virchow Klinikum, Berlin, Germany; †Imperial College London, London, United Kingdom; ‡Gynäkologie & Gynäkologische Onkologie, Dr. Horst Schmidt Klinik, Wiesbaden; §Frauenklinik Universitätsklinikum Ulm, Ulm; ∥Coordinating Center for Clinical Trials, University Marburg, Marburg; ¶Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg; #Referenzzentrum für Gynäkopathologie, Institut für Pathologie, Mannheim; **Frauen- und Poliklinik, Klinikum der Technischen Universität, Muenchen; ††Frauenklinik Universitätsklinikum Tuebingen, Tuebingen; ‡‡Frauenheilkunde und Geburtshilfe, Klinikum der J.W. Goethe-Universität, Frankfurt; §§Klinik für Frauenheilkunde und Geburtshilfe der Universität Duisburg-Essen, Essen; ∥∥Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Technische Universität Dresden, Dresden; ¶¶Zentrum für Gynäkologische Onkologie, Kiel; ##Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; ***Universitätsklinik und Poliklinik für Gynäkologie, Universitätsklinikum, Halle; and †††Gynäkologie & Gynäkologische Onkologie, Kliniken Essen-Mitte, Essen, Germany.
authors.forename: Christina
authors.initials: C
authors.lastname: Fotopoulou
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Nina
authors.initials: N
authors.lastname: Ewald-Riegler
authors.forename: Nikolaus
authors.initials: N
authors.lastname: de Gregorio
authors.forename: Alexander
authors.initials: A
authors.lastname: Reuss
authors.forename: Rolf
authors.initials: R
authors.lastname: Richter
authors.forename: Sven
authors.initials: S
authors.lastname: Mahner
authors.forename: Friedrich
authors.initials: F
authors.lastname: Kommoss
authors.forename: Barbara
authors.initials: B
authors.lastname: Schmalfeldt
authors.forename: Tanja
authors.initials: T
authors.lastname: Fehm
authors.forename: Lars
authors.initials: L
authors.lastname: Hanker
authors.forename: Pauline
authors.initials: P
authors.lastname: Wimberger
authors.forename: Ulrich
authors.initials: U
authors.lastname: Canzler
authors.forename: Jacobus
authors.initials: J
authors.lastname: Pfisterer
authors.forename: Stefan
authors.initials: S
authors.lastname: Kommoss
authors.forename: Steffen
authors.initials: S
authors.lastname: Hauptmann
authors.forename: Andreas
authors.initials: A
authors.lastname: du Bois
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000175:diagnosis*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018284:Cystadenocarcinoma, Serous / Q000097:blood / Q000175:diagnosis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis*; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins